- Home
- INTS vs BOLT Comparison
INTS vs BOLT Comparison
Compare INTS & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- BOLT
- Stock Information
- Founded
- INTS 2012
- BOLT 2015
- Country
- INTS United States
- BOLT United States
- Employees
- INTS N/A
- BOLT N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- INTS Health Care
- BOLT Health Care
- Exchange
- INTS Nasdaq
- BOLT Nasdaq
- Market Cap
- INTS 12.2M
- BOLT 11.5M
- IPO Year
- INTS 2023
- BOLT 2021
- Fundamental
- Price
- INTS $0.62
- BOLT $5.60
- Analyst Decision
- INTS Strong Buy
- BOLT Buy
- Analyst Count
- INTS 4
- BOLT 4
- Target Price
- INTS $4.50
- BOLT $34.00
- AVG Volume (30 Days)
- INTS 85.6M
- BOLT 26.4K
- Earning Date
- INTS 11-17-2025
- BOLT 11-14-2025
- Dividend Yield
- INTS N/A
- BOLT N/A
- EPS Growth
- INTS N/A
- BOLT N/A
- EPS
- INTS N/A
- BOLT N/A
- Revenue
- INTS N/A
- BOLT $4,167,000.00
- Revenue This Year
- INTS N/A
- BOLT N/A
- Revenue Next Year
- INTS N/A
- BOLT N/A
- P/E Ratio
- INTS N/A
- BOLT N/A
- Revenue Growth
- INTS N/A
- BOLT N/A
- 52 Week Low
- INTS $0.19
- BOLT $4.59
- 52 Week High
- INTS $3.40
- BOLT $13.80
- Technical
- Relative Strength Index (RSI)
- INTS 57.24
- BOLT 47.49
- Support Level
- INTS $0.23
- BOLT $5.65
- Resistance Level
- INTS $1.74
- BOLT $5.93
- Average True Range (ATR)
- INTS 0.14
- BOLT 0.32
- MACD
- INTS 0.06
- BOLT -0.05
- Stochastic Oscillator
- INTS 25.69
- BOLT 9.31
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.